Literature DB >> 22516401

Differences in neointimal thickness between the adluminal and the abluminal sides of malapposed and side-branch struts in a polylactide bioresorbable scaffold: evidence in vivo about the abluminal healing process.

Juan Luis Gutiérrez-Chico1, Frank Gijsen, Evelyn Regar, Jolanda Wentzel, Bernard de Bruyne, Leif Thuesen, John Ormiston, Dougal R McClean, Stephan Windecker, Bernard Chevalier, Dariusz Dudek, Robert Whitbourn, Salvatore Brugaletta, Yoshinobu Onuma, Patrick W Serruys.   

Abstract

OBJECTIVES: The goal of this study was to describe the neointimal healing on the abluminal side (ABL) of malapposed (ISA) struts and nonapposed side-branch (NASB) struts in terms of coverage by optical coherence tomography (OCT) and in comparison with the adluminal side (ADL).
BACKGROUND: The neointimal healing on the ABL of ISA and NASB struts has never to our knowledge been explored in vivo and could be involved in the correction of acute malapposition. The bioresorbable vascular scaffold (BVS) is made of a translucent polymer that enables imaging of the ABL with OCT.
METHODS: Patients enrolled in the ABSORB B (ABSORB Clinical Investigation Cohort B) study were treated with implantation of a BVS and imaged with OCT at 6 months. Thickness of coverage on the ADL and ABL of ISA and NASB struts was measured by OCT.
RESULTS: Twenty-eight patients were analyzed; 114 (2.4%) struts were malapposed or at side branches. In 76 ISA struts (89.4%) and 29 NASB struts (100%), the thickness of ABL coverage was >30 μm. Coverage was thicker on the ABL than on the ADL side (101 vs. 71 μm; 95% confidence interval [CI] of the difference: 20 to 40 μm). In 70 struts (60.7%, 95% CI: 50.6% to 70.0%), the neointimal coverage was thicker on the ABL, versus only 20 struts (18.5%, 95% CI: 11.6% to 28.1%) with thicker neointimal coverage on the ADL side (odds ratio: 3.35, 95% CI: 2.22 to 5.07).
CONCLUSIONS: Most of the malapposed and side-branch struts are covered on the ABL side 6 months after BVS implantation, with thicker neointimal coverage than on the ADL side. The physiological correction of acute malapposition involves neointimal growth from the strut to the vessel wall or bidirectional. (ABSORB Clinical Investigation, Cohort B [ABSORB B]; NCT00856856).
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22516401     DOI: 10.1016/j.jcin.2011.12.015

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  10 in total

1.  Effect of strut distribution on neointimal coverage of everolimus-eluting bioresorbable scaffolds: an optical coherence tomography study.

Authors:  Takao Sato; John Jose; Abdelhakim Allai; Mohamed El-Mawardy; Ralph Tölg; Gert Richardt; Mohamed Abdel-Wahab
Journal:  J Thromb Thrombolysis       Date:  2017-08       Impact factor: 2.300

2.  Neointimal response to everolimus-eluting bioresorbable scaffolds implanted at bifurcating coronary segments: insights from optical coherence tomography.

Authors:  Takao Sato; John Jose; Mohamed El-Mawardy; Dmitriy S Sulimov; Ralph Tölg; Gert Richardt; Mohamed Abdel-Wahab
Journal:  Int J Cardiovasc Imaging       Date:  2016-10-18       Impact factor: 2.357

3.  Superficial wall stress: the long awaited comprehensive biomechanical parameter to objectify and quantify our intuition.

Authors:  Juan Luis Gutiérrez-Chico
Journal:  Int J Cardiovasc Imaging       Date:  2018-06-06       Impact factor: 2.357

4.  The Role of Bioresorbable Scaffolds in Meeting the Challenges of Bifurcations.

Authors:  Axel Schmermund; Holger Eggebrecht
Journal:  Interv Cardiol       Date:  2013-08

5.  Post-dilatation after implantation of bioresorbable everolimus- and novolimus-eluting scaffolds: an observational optical coherence tomography study of acute mechanical effects.

Authors:  Florian Blachutzik; Niklas Boeder; Jens Wiebe; Alessio Mattesini; Oliver Dörr; Astrid Most; Timm Bauer; Jens Röther; Monique Tröbs; Christian Schlundt; Stephan Achenbach; Christian W Hamm; Holger M Nef
Journal:  Clin Res Cardiol       Date:  2016-10-18       Impact factor: 5.460

6.  Branch ostial optimization treatment and optimized provisional t-stenting with polymeric bioresorbable scaffolds: Ex-vivo morphologic and hemodynamic examination.

Authors:  Wei Cai; Lianglong Chen; Linlin Zhang; Sheng Tu; Lin Fan; Zhaoyang Chen; Yukun Luo; Xingchun Zheng
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

7.  Prospective evaluation of an ultrathin strut biodegradable polymer-coated sirolimus-eluting stent: 12 months' results from the S-FLEX UK registry.

Authors:  Anirban Choudhury; Scot Garg; Jamie Smith; Andrew Sharp; Sergio Nabais de Araujo; Anoop Chauhan; Nikhil Patel; Benjamin Wrigley; Sudipta Chattopadhyay; Azfar G Zaman
Journal:  BMJ Open       Date:  2019-10-11       Impact factor: 2.692

8.  Bioresorbable vascular scaffolds in saphenous vein grafts (data from OCTOPUS registry).

Authors:  Tomasz Roleder; Wojciech Wanha; Grzegorz Smolka; Jacek Zimoch; Andrzej Ochała; Wojciech Wojakowski
Journal:  Postepy Kardiol Interwencyjnej       Date:  2015-01-12       Impact factor: 1.426

9.  Clinical outcomes in 995 unselected real-world patients treated with an ultrathin biodegradable polymer-coated sirolimus-eluting stent: 12-month results from the FLEX Registry.

Authors:  Pedro A Lemos; Prakash Chandwani; Sudheer Saxena; Padma Kumar Ramachandran; Atul Abhyankar; Carlos M Campos; Julio Flavio Marchini; Micheli Zanotti Galon; Puneet Verma; Manjinder Singh Sandhu; Nikhil Parikh; Ashok Bhupali; Sharad Jain; Jayesh Prajapati
Journal:  BMJ Open       Date:  2016-02-17       Impact factor: 2.692

10.  Multimodality intravascular imaging of bioresorbable vascular scaffolds implanted in vein grafts.

Authors:  Tomasz Roleder; Elzbieta Pociask; Wojciech Wanha; Pawel Gasior; Magdalena Dobrolinska; Magdalena Garncarek; Przemyslaw Pietraszewski; Radoslaw Kurzelowski; Grzegorz Smolka; Wojciech Wojakowski
Journal:  Postepy Kardiol Interwencyjnej       Date:  2019-06-26       Impact factor: 1.426

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.